electroCore Q3 revenue rises on VA prescription growth

What happened

ElectroCore said third-quarter revenue rose 12% year over year, mainly on higher U.S. prescription sales to the Department of Veterans Affairs, but missed analyst expectations. Its net loss narrowed 61%, and it revised its 2026 revenue outlook to a range while projecting 2027 growth.

Confirmed

Global impact / market context

Higher U.S. Department of Veterans Affairs prescriptions supported sales, while favorable product mix and tighter cost controls helped reduce losses. However, revenue missed estimates and the company cut its 2026 outlook, making execution on sales growth and spending discipline important to its path toward positive adjusted EBITDA.

Analyst inference

The report combines improving year-over-year results with a near-term forecast reset: revenue grew and losses narrowed, but sales fell short of analyst expectations and 2026 guidance was reduced. The company also links future growth to salesforce expansion and possible FDA clearance for a broader Quell label.

Confirmed

What to watch

1. Track whether higher VA prescription sales for Quell Fibromyalgia and gammaCore continue, because the company identified them as the main drivers of third-quarter revenue growth. Analyst inference
2. Watch for FDA clearance of the possible Quell label expansion, which means broadening the product’s approved uses; the company includes this possibility in its outlook assumptions. Proposed
3. Assess whether salesforce expansion can support the revised 2026 revenue outlook and later growth while cost controls and commercial efficiency continue to limit operating losses. Analyst inference

Evidence

• Original source link unavailable